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Abstract
Background: Surveillance of drug resistance in antiretroviral treatment-naı̈ve patients in China is needed to ensure optimal
treatment outcomes and control of the human immunodeficiency virus (HIV) epidemic.
Methods: A systematic literature search was conducted in English and Chinese through PubMed (English), China National
Knowledge Infrastructure (Chinese), Chinese Biomedical Literature Database (Chinese), and Wanfang (Chinese). Random
effects models were used to calculate the pooled prevalence of transmitted drug resistance and subgroup analyses
examined prevalence estimates across time periods, study locations, and study populations.
Results: Analysis of data from 71 studies (47 in Chinese and 24 in English) yielded a pooled prevalence of transmitted HIV
drug resistance to any antiretroviral drug class of 3.64% (95% confidence interval [CI]: 3.00%–4.32%). Rates were significantly
high at initial stage of free ART program from 2003 to 2005 (5.18%, 95%CI: 3.13%–7.63%), and were much lower among
studies conducted in 2006–2008 (3.02%, 95%CI: 2.03%–4.16%). A slight increase was observed again in the most recent
study period from 2009 to 2012 (3.68%, 95%CI: 2.78%–4.69%). Subgroup analysis revealed highest prevalence levels of
transmitted drug resistance in Beijing city, and Henan and Hubei provinces (above 5%), and although differences in
prevalence rates among risk groups were negligible, men who have sex with men were unique in their relatively large
portion of protease inhibitor resistance, a second-line drug of limited availability in China.
Conclusions: Overall prevalence of transmitted HIV drug resistance in China is classified as ‘‘low’’ by the World Health
Organization. However regional and temporal variability suggest a more complex epidemic for which closer HIV drug
resistance surveillance is needed. A nationwide HIV drug resistance surveillance system to monitor both treatment-
experienced and treatment-naı̈ve patients will be a cornerstone to ensure the effectiveness of treatment scale-up,
particularly as China seeks to expand a national policy of antiretroviral treatment as prevention.
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Introduction
China has one of the largest populations of persons infected with
human immunodeficiency virus type-1(HIV-1). As of 2011 an
estimated 780,000 people living with HIV/AIDS and among them
154,000 living with AIDS in China [1]. The HIV epidemic is
largely concentrated in injecting drug users (IDU), as well as in
groups with higher risk sexual exposures including female sex
workers and men who have sex with men (MSM) [2]. As of 2007,
however, data from the national case report system has suggested
that heterosexual transmission (HST) has become the primary
mode of transmission in China, signaling a potential transmission
to a more generalized epidemic [1].Of the about 70,000 new HIV
diagnoses from January to September in 2013, those believe to be
acquired through unprotected sex accounted for 89.9% (hetero-
sexual transmission for 69.1%, homosexual transmission for
20.8%) [3].
To combat the spread of HIV through the general population,
the Chinese Center for Disease Control has launched a policy
initiative to harness suppressive antiretroviral therapy (ART) to
slow the spread of HIV in China. The existing national free ART
program established in 2003, is expected to provide a strong
foundation for such an effort. Initially started as a pilot program
for patients who were former plasma donors (FPD), the program
has undergone rapid scale up [4,5]. And by the end of September
2013, the national free ART program has treated about 260,000
cumulative patients [3], and has reduced AIDS associated
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mortality from 39.3 to 14.2 deaths per 100 persons from 2002 to
2009 [6].
Rapid scale up of ART access has been accompanied by a
concomitant rise in drug resistance among treated HIV patients.
This has been largely attributed to the limited selection of antiviral
agents through the national ART program on which most patients
rely, and the lack of critical disease monitoring tools like CD4 or
viral load testing in most treatment settings [5,7,8]. Though the
relationship between poor treatment outcomes, insufficient viral
suppression, and emerge of drug resistance is well understood
[9,10], little is known about onward transmission of resistant
strains in Chinese settings. Primary infection with drug resistant
strains severely limits new patients’ treatment options and shortens
time to treatment failure. The prevalence of transmitted drug
resistance (TDR) in wider circulation could also undermine
program efficacy of the national treatment efforts [11]. A better
understanding of the prevalence of drug resistance in treatment
naı̈ve HIV/AIDS patients in China will provide insight critical for
both clinical management and for broader disease control efforts
[12].
The goal of this systematic review is to provide an overview and
pooled prevalence estimate of HIV drug resistance among
treatment-naı̈ve patients in China. We also provide a simple
analysis of several trends and distributions available from the data
in order to provide more insight into better treatment and control
of HIV in China.
Methods
Search strategy
We conducted a systematic literature in English and Chinese
using the following four databases: PubMed, China National
Knowledge Infrastructure (CNKI), Chinese Biomedical Literature
Database (CBM), and Wanfang, from January 1, 1990 through
February 28, 2014. Search terms included (‘‘HIV’’ OR ‘‘AIDS’’
OR ‘‘human immunodeficiency virus’’ OR ‘‘acquired immuno-
deficiency syndrome’’) AND (‘‘drug resistance’’ or ‘‘drug resis-
tant’’) AND (‘‘China’’). Details on search strategy can be found in
the Appendix S1. We further reviewed the reference lists for other
relevant articles not captured in our initial search.
Selection Criteria
Investigators YYS and HXL independently assessed eligibility of
articles and performed the data extraction. Discrepancies between
the two investigators were resolved by consulting the other authors
(NW and MKS). Eligible articles all met the following inclusion
criteria: (1) inclusion of data on HIV-1-infected and treatment-
naı̈ve individuals; (2) availability of basic demographic information
for study subjects such as age, sex, or most likely HIV transmission
route; (3) availability of information on study design, location, and
period; and (4) HIV drug resistance patterns were interpreted
using the WHO recommended Stanford HIV Drug Resistance
Database (http://hivdb.stanford.edu). Articles that restricted study
subjects to HIV patients of a single subtype were excluded, as were
those without information on patient treatment status or that
pooled results of treated and untreated patients. Studies based
outside of mainland China such as Taiwan, Hong Kong and
Macao were excluded due to the fact that these regions maintain
autonomous and separate HIV/AIDS treatment programs.
Articles based on the same or overlapping study populations were
included only once to avoid duplication, with preference given to
the article with more detailed information about the population,
or, all else equal, with the larger sample size.
Data extraction
A standardized form was used to assess article eligibility and to
extract data including author names, year of publication, study
period, language of article, study location, age range and sex of
participants, most likely routes of primary HIV infection, time of
infection(chronic or new diagnose), study design (cohort vs. cross
section), recruitment method, system of HIV drug resistance
typing, portion of tested samples whose HIV RNA was successfully
amplified and sequenced, and characteristics of the sequences
genotype including number of mutations with at least low-level
resistance 1) to any antiretroviral agent, 2) to nucleoside reverse
transcriptase inhibitor(NRTI), 3) to non-nucleoside reverse tran-
scriptase inhibitor(NNRTI), 4) to protease inhibitor(PI).
Statistical analysis
The proportion of TDR was defined as number of samples
exhibiting at least a lower-level resistance to any antiretroviral
agent, divided by the total number of samples successfully
amplified and sequenced [13]. This definition of TDR prevalence
is consistent with that used for the WHO TDR surveillance
mutation list [14]. The Freeman-Tukey Double arcsine transfor-
mation of proportions was used to calculate an overall proportion.
Model choice (fixed versus random effects models) was based on
heterogeneity assessment by examining the Cochran Q statistic (p-
value of ,0.1 was considered a statistically significant) [15] and
the I2 statistic (values of 25%, 50% and 75% are considered to
represent low, medium and high heterogeneity respectively) [16].
The DerSimonian-Laird estimate was used in case of random
effects. Subgroup analyses were conducted according to study
period, study location and study population to assess the
heterogeneity between studies. Publication bias was assessed with
the funnel plot and Egger’s test, which found no evidence of bias
(Figure S1). Analyses were carried out using R EpiTools package
[17] and SAS(version 9.3, SAS Institute).
Results
Study selection and characteristics
Of the 4964 articles (4656 in Chinese, 308 in English) initially
identified, of which 1934 were excluded as duplicates, another
2858 were removed for relevance based on a title and abstract
screening. Following a closer full text review of the remaining 172
articles we identified 71 studies for inclusion in the final analysis, of
which 47 were in Chinese, 24 in English (Figure 1). Seventeen of
these employed the WHO HIV drug resistance survey method
which recommends use of truncated sequential sampling (TSS) to
classify levels of transmitted drug resistance for each drug class in
resource poor settings [18]. Among the remainder, 54 were cross-
sectional studies. Details on resistance to specific classes of
antiretroviral drug were available in 68 studies (Table S1).
Transmitted drug resistance prevalence rates
The 71 studies included in this analysis represented results from
a collective total of 11,633 HIV-1 treatment naı̈ve individuals,
among whom 9,167 HIV RNA sequences were successfully
amplified and analyzed. The random effects estimate for overall
pooled prevalence of HIV-1 TDR to any antiretroviral drug was
3.64% (95% confidence interval [CI]: 3.00%–4.32%). The pooled
prevalence of mutations resistant to NRTI’s, NNRTI’s, and PI’s
was 0.91% (95%CI: 0.60%–1.27%), 1.14% (95%CI: 0.75%–
1.59%), 0.68% (95%CI: 0.41%–1.01%), respectively.
TDR prevalence was further explored within identifiable
subgroups in studies where relevant information was provided
(Table 1). Figure 2 shows temporal trends in TDR prevalence
HIV Transmitted Drug Resistance in China: A Meta-Analysis
PLOS ONE | www.plosone.org 2 October 2014 | Volume 9 | Issue 10 | e110652
according to the midpoint of the year in which study participants
were recruited. A slightly upward trend can be detected in the
composite time trend, though the trend was not statistically
significant. We further categorized study times into four time
periods roughly corresponding to the following phases of the
national free ART program: pilot (before 2003), initiation (2003 to
2005), scale-up (2006 to 2008), and introduction of second line
therapy (2009–2012) [5,8]. Results of the analyses showed that the
overall TDR prevalence for any antiretroviral drug class was
significantly high at initial stage of free ART program (5.18%,
95%CI: 3.13%–7.63%), but much lower during the scale-up phase
(3.02%, 95%CI: 2.03%–4.16%). TDR prevalence rose again
slightly after 2008 (3.68%, 95%CI: 2.78%–4.69%). Geographic
subgroup analyses excluded studies in which the study represented
the sole report on TDR from a given province [19–23] or in which
results were reported as pooled prevalence of patients from
multiple provinces [24–32]. Stratified analyses showed that TDR
prevalence rates in the city of Beijing and the provinces of Henan
and Hubei were all above 5%, but the rest were below this
threshold. Finally, where information on most likely routes of HIV
infection was provided, we estimated TDR prevalence for the
following groups: FPD (5 articles), MSM (17 articles), IDU (5
articles), and those otherwise described as heterosexual individuals
(3 articles). Pooled prevalence of TDR in these four risk groups
were highest among MSM (4.03%, 95%CI:2.81%–5.43%), and
slightly lower among FPD (3.78%, 95% CI: 2.48%–5.31%) and
heterosexuals (3.73%, 95% CI: 1.85%–6.20%). Rates were lowest
among IDU (2.78%, 95% CI: 1.04%–5.12%), but substantial
overlap of the 95% confidence intervals suggests no significant
difference in TDR rates among these groups. Figure 3 shows the
prevalence of TDR to specific classes of antiretroviral drug within
each subgroup, in which a disproportionately large prevalence of
PIs resistance can be seen in MSM.
Discussion
Our meta-analysis showed that estimated prevalence of TDR in
ART-naı̈ve patients in China was 3.64% (95%CI: 3.00%–4.32%).
Such a pooled prevalence rate of primary drug resistance is similar
to those from other developing country settings such as Thailand
(0.5%, 95% CI: 0.1%–1.4%) and India (2.7%, 95% CI: 1.1%–
4.7%) [33], but lower than those estimated in Europe (8.4%,
95%CI: 7.4%–9.5%) [34] and the United States (14.6%, 95% CI:
12.9%–16.0%) [35]. The far lower rates of TDR in Chinese HIV
patients as compared to those in western countries may be due to
differences in sampling strategies, but may also reflect real
differences in the prevalence of circulating strains of drug
resistance HIV in the two settings. China’s HIV epidemic is at a
relatively earlier phase compared to those in Africa and the west,
as has a shorter history of population level exposure to ART,
leading to less drug resistance in the population.
Changes in estimated TDR prevalence across populations
sampled over distinct time periods likely reflect population level
response to the antiretroviral drug used most widely by
beneficiaries of China’s free ART program at each phase. Higher
Figure 1. Flow chart of the process of studies selection.
doi:10.1371/journal.pone.0110652.g001
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TDR prevalence estimates in the earliest phase of the national free
ART program may be due to the widespread use of generic agents
including zidovudine, didanosine, and nevirapine [5]. Subsequent
survey work as shown a strong association between didanosine use
and virological failure in the earliest participants of the free ART
program, suggesting high drug resistance rates due to antiretro-
viral drug choice [36,37]. In addition, ART dispensation in the
early phase of the epidemic relied on village clinics where
clinicians who often lacked formal medical training and who
worked without the benefit of routine laboratory monitoring to aid
their patient management [5,7,38]. After 2005, routinization of
ART practices [39] and availability of branded drugs including
lamivudine and efavirenz may have led to lower population level
prevalence of drug resistant strains [4]. Slightly higher rates of
TDR following 2008 may be due to broad expansion of ART
access during this phase [8,40] or due to a cumulative increase in
the prevalence of drug strains in HIV infected person on therapy
[41]. However the lack of a statistically significant difference in
pooled prevalence of TDR in these two periods may reflect a
spurious difference.
Geographic sub-analyses showed that pooled estimates of TDR
were highest in Beijing (a provincial-level city) and Henan and
Hubei provinces. Higher rates of TDR in Beijing may be due to
the fact that three out of the five studies based in Beijing were of
MSM [42–44]. Past reports of TDR in MSM in Beijing have been
high [42]—as compared to rates among MSM recruited in
Guangzhou city [45], Liaoning province [46] and Yunnan
province [47]—but for reasons that are still poorly understood.
Higher rates in Henan province likely reflect the fact that it has the
largest concentration of treated HIV patients in China with the
earliest access to ART due to the piloting of the national treatment
program in this population [4]. Finally, the three articles
conducted in Hubei province were carried out in the early phase
of the free ART program, a possible explanation for the higher
prevalence of TDR.
Though drug resistance patterns did not vary significantly
across risk populations, one noteworthy finding was the elevated
prevalence of PI-specific TDR among MSM. The fact that PI’s
were not available through China’s free ART program until
2008 [48] and its limited use even today [25] may suggest
acquisition of PI-specific TDR from individuals treated outside of
Table 1. Result of stratified meta-analysis based on time period, study region and risk group.
Category Number of estimates Pooled prevalence (%) 95%CI (%) Heterogeneity p-valuea
Time periodb
before 2003 3 2.65 0.89–5.17 0.15
2003–2005 5 5.18 3.13–7.63 0.01
2006–2008 20 3.02 2.03–4.16 0.18
2009–2012 53 3.68 2.78–4.69 ,0.0001
Regionc
Hubei 3 7.37 4.61–10.65 0.42
Henan 7 7.11 4.10–10.80 0.00
Beijing 5 6.52 4.35–9.05 0.27
Shanghai 3 4.91 2.25–8.38 0.87
Tianjin 2 4.90 1.25–10.31 0.65
Zhejiang 2 4.76 2.35–7.86 0.51
Liaoning 2 4.40 2.26–7.15 0.95
Guangdong 7 3.43 2.17–4.91 0.70
Guangxi 6 2.72 1.70–3.94 0.14
Hunan 2 2.69 0.91–5.22 0.83
Yunnan 11 2.44 1.14–4.11 0.08
Guizhou 2 2.25 0.00–14.08 0.04
Anhui 3 1.89 0.02–5.51 0.60
Shandong 2 1.56 0.07–4.24 0.67
Sichuan 3 0.49 0.00–2.16 0.24
Risk groupd
MSM 17 4.03 2.81–5.43 0.05
FPD 5 3.78 2.48–5.31 0.19
HST 3 3.73 1.85–6.20 0.05
IDU 5 2.78 1.04–5.12 0.22
Note: aHeterogeneity p value was calculated by examining the Cochran Q statistic (p-value of ,0.1 was considered a statistically significant); bFor time period subgroup
analysis, 81 HIV TDR prevalence estimates from 71 articles were used; cFor study region subgroup analysis, 60 HIV TDR prevalence estimates from 58 articles were used;
dFor risk group subgroup analysis, 30 HIV TDR prevalence estimates from 28 articles were used. MSM: men who have sex with men; FPD: former plasma donors; HST:
Heterosexual transmission; IDU: Injecting drug users.
doi:10.1371/journal.pone.0110652.t001
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the free ART program or foreign nationals treated abroad.
Mixing between foreign-born and Chinese men in MSM sexual
networks, and the relative affluence of MSM (or the subset
captured in epidemiological studies) which allows for increased
international travel [25] may be partial explanations for this
phenomenon.
Our analysis faces several important limitations. Convenience
sampling was the most common recruitment method for most
studies included in this analysis which limits representativeness of
findings. Selection bias may also have led to oversampling of
studies in regions with high levels of ART penetration such as
Guangdong, Beijing, Yunnan, Henan and Guangxi.
Despite these limitations, findings from this study represent the
first comprehensive investigation of HIV TDR in treatment naı̈ve
individuals in China. Though estimated rates are lower than many
western settings, the relative infancy of the Chinese ART program
underscores the importance of consistent monitoring of onward
transmission of drug resistant HIV at the population level. Beyond
the clinical considerations of limited therapeutic options for TDR
in treatment naı̈ve patients, China’s focus on treatment as
prevention as part of its newly articulated HIV control strategy
in the 12th Five-Year Action Plan [12] underscores the HIV
prevention tradeoffs of expanded ART access.
Figure 2. Temporal trends of prevalence of drug resistance in HIV ART-naı̈ve patients in China. The size of circle correspond to sample
size of every study, 81 estimates from 71 articles were used in this subgroup analysis.
doi:10.1371/journal.pone.0110652.g002
Figure 3. Prevalence of transmitted drug resistance in difference risk groups. Note: MSM: men who have sex with men; HST: Heterosexual
transmission; FPD: former plasma donors; IDU: Injecting drug users; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse
transcriptase inhibitor; PI: protease inhibitor.
doi:10.1371/journal.pone.0110652.g003
HIV Transmitted Drug Resistance in China: A Meta-Analysis
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e110652
Supporting Information
Figure S1 Funnel plot.
(DOC)
Table S1 Characteristics of included studies.
(DOC)
Checklist S1 PRISMA checklist.
(DOC)
Appendix S1 Detailed search strategy.
(DOCX)
Author Contributions
Conceived and designed the experiments: YYS NW. Performed the
experiments: YYS HXL LZ MKS. Analyzed the data: YYS. Contributed
reagents/materials/analysis tools: FJZ MKS LZ JW. Wrote the paper:
YYS FJZ HXL MKS LZ JW NW.
References
1. Ministry of Health, People’s Republic of China, Joint United Nations
Programme on HIV/AIDS, World Health Organization (2011) 2011 Estimates
for the HIV/AIDS Epidemic in China. Beijing, China.
2. Zhang L, Chow EP, Jing J, Zhuang X, Li X, et al. (2013) HIV prevalence in
China: integration of surveillance data and a systematic review. Lancet Infect
Dis 13: 955–963.
3. National Health and Family Planning Commission of the People’s Republic of
China (2013) Background of HIV/AIDS prevention and control in China.
Available: http://www.nhfpc.gov.cn/jkj/s3586/201312/2b871ccd2ef446eb954
2875d3d68bbca.shtml. Accessed March 31, 2014.
4. Dou Z, Chen RY, Xu J, Ma Y, Jiao JH, et al. (2010) Changing baseline
characteristics among patients in the China National Free Antiretroviral
Treatment Program, 2002-09. Int J Epidemiol 39 Suppl 2: ii56–64.
5. Zhang F, Haberer JE, Wang Y, Zhao Y, Ma Y, et al. (2007) The Chinese free
antiretroviral treatment program: challenges and responses. AIDS 21 Suppl 8:
S143–148.
6. Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, et al. (2011) Effect of earlier initiation
of antiretroviral treatment and increased treatment coverage on HIV-related
mortality in China: a national observational cohort study. Lancet Infect Dis 11:
516–524.
7. Zhang FJ, Pan J, Yu L, Wen Y, Zhao Y (2005) Current progress of China’s free
ART program. Cell Res 15: 877–882.
8. Zhao DC, Wen Y, Ma Y, Zhao Y, Zhang Y, et al. (2012) Expansion of China’s
free antiretroviral treatment program. Chin Med J (Engl) 125: 3514–3521.
9. Little SJ (2000) Transmission and prevalence of HIV resistance among
treatment-naive subjects. Antivir Ther 5: 33–40.
10. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF (2008) The World Health
Organization’s global strategy for prevention and assessment of HIV drug
resistance. Antivir Ther 13 Suppl 2: 1–13.
11. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, et al. (2011)
Effect of transmitted drug resistance on virological and immunological
response to initial combination antiretroviral therapy for HIV (EuroCoord-
CHAIN joint project): a European multicohort study. Lancet Infect Dis 11: 363–
371.
12. Zhao Y, Poundstone KE, Montaner J, Wu ZY (2012) New policies and strategies
to tackle HIV/AIDS in China. Chin Med J (Engl) 125: 1331–1337.
13. Avila-Rios S, Garcia-Morales C, Garrido-Rodriguez D, Ormsby CE, Hernan-
dez-Juan R, et al. (2011) National prevalence and trends of HIV transmitted
drug resistance in Mexico. PLoS One 6: e27812.
14. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug
resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009
update. PLoS One 4: e4724.
15. Higgins J, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis.
Statistics in medicine 21: 1539–1558.
16. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J (2006)
Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol
Methods 11: 193–206.
17. R Core Team (2013) R: A language and environment for statistical computing.
R Foundation for Statistical Computing, Vienna, Austria. Available: http://
www.R-project.org/. Accessed April 7, 2014.
18. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF (2008)
Recommendations for surveillance of transmitted HIV drug resistance in
countries scaling up antiretroviral treatment. Antivir Ther 13 Suppl 2: 25–36.
19. Qiu LJ, Wu SL, Liu XH, Xie MR, Yan PP, et al. (2013) Study on drug resistant
mutations for HIV-1 strains in Fujian Province. Chin J AIDS STD 19: 6–9.
20. Li L, Lu X, Li H, Chen L, Wang Z, et al. (2011) High genetic diversity of HIV-1
was found in men who have sex with men in Shijiazhuang, China. Infect Genet
Evol 11: 1487–1492.
21. Li WJ, Li H, Wang FX, Li YG (2012) Drug resistance mutations in HIV-1
strains of treatment-naive patients in Harbin, China. Chin J Viral Dis 2:
40–45.
22. Yang HT, Xiao ZP, Huang XP, Hu HY, Xu XQ, et al. (2012) Threshold survey
of transmitted HIV-1 drug resistance in Jiangsu province. Acta Universitatis
Medicinalis Nanjing (Natural Science) 2012: 1–5.
23. Han XX, Zhao B, Sun F, An MM, Yin LL, et al. (2012) Primary HIV-1drug
resistance among injecting drug users in Xinjiang. Chin J Public Health 28:
810–811.
24. Liao L, Xing H, Li X, Ruan Y, Zhang Y, et al. (2007) Genotypic analysis of the
protease and reverse transcriptase of HIV type 1 isolates from recently infected
injecting drug users in western China. AIDS Res Hum Retroviruses 23: 1062–
1065.
25. Yang J, Xing H, Niu J, Liao L, Ruan Y, et al. (2013) The emergence of
HIV-1 primary drug resistance genotypes among treatment-naive men who
have sex with men in high-prevalence areas in China. Arch Virol 158:
839–844.
26. Kuang JQ (2007) Genotypic HIV-1 Drug Resistance and Factors associated with
the effect of Antiretroviral therapy Among Chinese HIV/AIDS Patients: Peking
Union Medical College.
27. Liao L, Xing H, Shang H, Li J, Zhong P, et al. (2010) The prevalence of
transmitted antiretroviral drug resistance in treatment-naive HIV-infected
individuals in China. J Acquir Immune Defic Syndr 53 Suppl 1: S10–14.
28. Wang X, He C, Xing H, Liao L, Xu X, et al. (2012) Short communication:
emerging transmitted HIV type 1 drug resistance mutations among patients
prior to start of first-line antiretroviral therapy in middle and low prevalence sites
in China. AIDS Res Hum Retroviruses 28: 1637–1639.
29. Li L, Sun G, Liang S, Li J, Li T, et al. (2013) Different Distribution of HIV-1
Subtype and Drug Resistance Were Found among Treatment Naive Individuals
in Henan, Guangxi, and Yunnan Province of China. PLoS One 8: e75777.
30. Si XF, Huang HL, Wei M, Guan Q, Song YH, et al. (2004) Prevalence of drug
resistance mutations among antiretroviral drug-naive HIV-1-infected patients in
China. Chinese J Exp Chin Virol 18: 308–311.
31. Zeng P, Wang J, Huang Y, Guo X, Li J, et al. (2012) The human
immunodeficiency virus-1 genotype diversity and drug resistance mutations
profile of volunteer blood donors from Chinese blood centers. Transfusion 52:
1041–1049.
32. Yin CY, Lu HZ, Huang XX, Li XO, Lou GQ, et al. (2011) HIV-1 drug-
resistance mutations in treatment-naive patients in China. Chin J Clin Infect Dis
4: 201–205.
33. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, et al. (2012) Global trends
in antiretroviral resistance in treatment-naive individuals with HIV after rollout
of antiretroviral treatment in resource-limited settings: a global collaborative
study and meta-regression analysis. Lancet 380: 1250–1258.
34. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, et al. (2009)
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 200:
1503–1508.
35. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, et al. (2010)
Prevalence of transmitted drug resistance associated mutations and HIV-1
subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 24: 1203–1212.
36. Li T, Dai Y, Kuang J, Jiang J, Han Y, et al. (2008) Three generic nevirapine-
based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric
observation cohort. PLoS One 3: e3918.
37. Xing H, Wang X, Liao L, Ma Y, Su B, et al. (2013) Incidence and associated
factors of HIV drug resistance in Chinese HIV-infected patients receiving
antiretroviral treatment. PLoS One 8: e62408.
38. Zhang FJ, Maria A, Haberer J, Zhao Y (2006) Overview of HIV drug resistance
and its implications for China. Chin Med J (Engl) 119: 1999–2004.
39. Manual for National free HIV antiretroviral drug treatment: first edition (2005)
Beijing: People’s Medical Publishing House.
40. World Health Organization (WHO) (2012) WHO HIV drug resistance report
2012. Available: http://www.who.int/hiv/pub/drugresistance/report2012/en/
. Accessed January 31, 2014.
41. Liao L, Xing H, Su B, Wang Z, Ruan Y, et al. (2013) Impact of HIV drug
resistance on virologic and immunologic failure and mortality in a cohort of
patients on antiretroviral therapy in China. AIDS 27: 1815–1824.
42. Zhang X, Li S, Li X, Li X, Xu J, et al. (2007) Characterization of HIV-1
subtypes and viral antiretroviral drug resistance in men who have sex with men
in Beijing, China. AIDS 21 Suppl 8: S59–65.
43. Wu YS, Zhang T, Wei FL, Li DM, Zhang WW, et al. (2011) Study on
transmitted drug resistance in new infected or recently infected patients. Chinese
Medical Association-Fifth national academic conferences of HIV/AIDS, viral
hepatitis C and tropical diseases. Wu Han, Hubei.
44. Li L, Han N, Lu J, Li T, Zhong X, et al. (2013) Genetic characterization and
transmitted drug resistance of the HIV type 1 epidemic in men who have sex
with men in Beijing, China. AIDS Res Hum Retroviruses 29: 633–637.
45. Zhao GL, Feng TJ, Hong FC, Wang F, Cai YM, et al. (2009) Study on drug-
resistant gene mutation in HIV-1 infected MSM population in Shenzhen.
Chin J AIDS STD 15: 589–591.
HIV Transmitted Drug Resistance in China: A Meta-Analysis
PLOS ONE | www.plosone.org 6 October 2014 | Volume 9 | Issue 10 | e110652
46. Zhao B, Han X, Dai D, Liu J, Ding H, et al. (2011) New trends of primary drug
resistance among HIV type 1-infected men who have sex with men in Liaoning
Province, China. AIDS Res Hum Retroviruses 27: 1047–1053.
47. Chen M, Ma Y, Su Y, Yang L, Zhang R, et al. (2014) HIV-1 Genetic
Characteristics and Transmitted Drug Resistance among Men Who Have Sex
with Men in Kunming, China. PLoS One 9: e87033.
48. Manual for National free HIV antiretroviral drug treatment: second edition
(2008) Beijing: People’s Medical Publishing House.
HIV Transmitted Drug Resistance in China: A Meta-Analysis
PLOS ONE | www.plosone.org 7 October 2014 | Volume 9 | Issue 10 | e110652
